Key facts
- Phlow’s last known valuation is $441.4M (Feb 2025).
- It has raised $91.5M; the latest was Later Stage VC ($30.5M) in Feb 2025.
- Notable investors include Virginia Innovation Partnership Corporation, Virginia Venture Partners, Align Private Capital, Bagel Boy Equity Group, Whole Orange Equity.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Phlow
- ·The full record, as it builds
Funding rounds
No funding rounds for Phlow are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phlow
Operator of a pharmaceutical company intended to provide low-cost pharmaceuticals and reduce dependency on foreign supply chains. The company's products include precursor chemical ingredients, active healthcare ingredients, and finished pharma products, domestically for essential medicines and to ensure quality, safety, and affordability, enabling practitioners to provide essential medicines to their patients.
- Sector
- Healthcare
- HQ
- Richmond, VA, United States
- Founded
- 2020
- Employees
- 113
- Website
- phlow-usa.com/
- Ownership
- Privately Held (backing)
Phlow doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phlow shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phlow in its N-PORT filings yet. We sweep new filings monthly.